Choose Your Location
|
![]() |
ABBOTT PARK, Ill. (Map) -
"The new formulation center is a clear example of Abbott's commitment to
advancing scientific innovation," said
The Formulation Development Center supports programs for both potent (drugs with highly active ingredients that require special handling) and non-potent oral compounds. This includes state-of-the-art capabilities for the safe formulation of potent compounds, such as cancer therapies, that are increasingly becoming more effective at low-dose levels.
Abbott's new facility is focused on transforming complex molecules from the laboratory into tablets and capsules that can be used in pre-clinical and clinical studies to determine safety and efficacy. Formulation is an important step in the research and development process, providing a crucial link between the laboratory and commercial manufacturing. Formulation and process work begins shortly after a candidate molecule is identified. Initial formulations are then refined as more information is gathered through the development process.
The center was specifically designed with cutting-edge equipment and improvements to advance the R&D process, including automated technologies that reduce the time for preparing, producing and refining pilot drug formulations. In addition, all of the equipment in the facility is aligned with the production equipment in Abbott's commercial manufacturing sites, which will allow for rapid scale-up of production as drug compounds move toward late-stage clinical trials and market availability for patients.
"We considered several locations for the new formulation center, but decided to strategically place the building in the midst of our other Abbott Park R&D facilities to provide easy access for our scientists, pharmacists and engineers," said Leonard.
Fast Facts for Abbott's New Formulation Development Center -- Location: Abbott Park, Ill. -- Size and structure: Two-story, 64,000-square-foot facility features a flexible design with modular walls and ceilings that will allow for rapid future expansion -- Key Current Formulation Programs: Currently developing oral formulations (capsule and tablet) for clinical studies involving new compounds to treat cancer, hepatitis, pain and other areas -- Investment: $53 million -- Facility Initiated/Completed: Groundbreaking in June 2005; Completed in January 2008 -- Personnel: Seventeen dedicated onsite employees; more than 40 additional staff regularly work in the facility
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.
|
|


